10-Q: FibroBiologics Reports Q1 2025 Results: Focus Remains on Clinical Development Amidst Ongoing Losses

FibroBiologics' Q1 2025 results reveal continued operating losses as the company progresses with its fibroblast-based therapies and prepares for clinical trials.

Summary

• FibroBiologics, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is focused on developing fibroblast-based therapies for chronic diseases.
• FibroBiologics has incurred operating losses since its inception and anticipates these losses will continue as it invests in infrastructure, intellectual property, and research and development.
• The company's net loss for the three months ended March 31, 2025, was $4.966 million, compared to a net loss of $8.460 million for the same period in 2024.
• As of March 31, 2025, FibroBiologics had an accumulated deficit of $40.484 million and cash and cash equivalents of $8.667 million.
• The company is planning to initiate a Phase 1/2 clinical trial in Australia for CYWC628 in the second half of 2025.
• FibroBiologics is also working on CybroCell and plans to amend its IND clearance with the FDA.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company has a Standby Equity Purchase Agreement (SEPA) in place and expects to receive proceeds from the third tranche of short-term convertible notes.
• The company issued 118,991 shares of Common Stock to satisfy the $250 thousand commitment fee payable.
• During the three months ended March 31,2025, $3,600 thousand of short-term convertible notes were converted into 2,530,591 shares of Common Stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to ongoing losses, concerns about the company's ability to continue as a going concern, and the need for additional funding. However, the company is making progress with its clinical development plans, which provides some optimism.

Positives

• The net loss decreased from $8.460 million in Q1 2024 to $4.966 million in Q1 2025.
• The company is progressing with its clinical development plans, including the planned Phase 1/2 trial for CYWC628.
• The company has a SEPA in place to provide access to additional capital.
• The company completed pre-clinical studies investigating multiple administrations of CYWC628 spheroids on a chemically induced chronic wound NONcNZO10/LtJ and BKS.Cg-Dock7m +/+ Leprdb/J mouse model.
• The company completed a Phase 1 study in Mexico using the fibroblast cell composition for patients with MS.
• The company received IND clearance from the FDA in 2018, conditional upon approval of our master cell bank, to evaluate this candidate in a planned clinical trial.

Negatives

• The company has incurred operating losses since inception and expects to continue incurring losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's accumulated deficit as of March 31, 2025, was $40.484 million.
• The company's cash and cash equivalents decreased from $13.985 million at the end of 2024 to $8.667 million as of March 31, 2025.
• The company does not generate revenues and may never achieve profitability.
• The company has a material weakness in its internal control over financial reporting due to a lack of segregation of duties.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company's product candidates are subject to regulatory approval, and there is no guarantee they will be approved.
• The company faces competition from other pharmaceutical companies.
• The company's intellectual property may not be adequately protected.
• The company may need to obtain additional funding, and there is no guarantee it will be available on favorable terms.
• The company has a material weakness in its internal control over financial reporting due to a lack of segregation of duties.
• The company is dependent on third parties for its cell therapy manufacturing process for the foreseeable future.

Future Outlook

The company plans to initiate a Phase 1/2 clinical trial for CYWC628 in Australia in the second half of 2025 and expects to complete the clinical trial in the first quarter of 2026. The company expects to carry out experiments to demonstrate the potential of using the CYWC628 master cell bank for use with the manufacturing of the CybroCell drug product.

Management Comments

• A transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company's cost structure.
• The Company currently does not generate revenues and may never achieve profitability.
• Unless and until such time that revenue and net income are generated, the Company will need to continue to raise additional capital.

Industry Context

FibroBiologics operates in the competitive biotechnology industry, focusing on cell-based therapies. The company's success depends on its ability to develop and commercialize innovative treatments for chronic diseases. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and the need for significant capital investment.

Comparison to Industry Standards

• It is difficult to compare FibroBiologics directly to industry standards due to its early stage and specific focus on fibroblast-based therapies.
• Comparable companies in the cell therapy space include companies like Vericel Corporation and Mesoblast, which are further along in the commercialization process.
• FibroBiologics' reliance on external funding and ongoing losses are common characteristics of early-stage biotech companies.
• The company's planned Phase 1/2 trial for CYWC628 is a key milestone, and its success will be crucial for attracting further investment and partnerships.

Stakeholder Impact

• Shareholders: The company's financial performance and ability to raise capital will directly impact shareholder value.
• Employees: The company's ability to continue as a going concern will impact job security and future opportunities.
• Customers: The company's success in developing and commercializing its product candidates will impact the availability of new treatments for chronic diseases.
• Suppliers: The company's financial stability will impact its ability to meet its contractual obligations with suppliers.
• Creditors: The company's ability to repay its debts will depend on its ability to generate revenue and raise additional capital.

Next Steps

• Initiate the twelve-week Phase 1/2 clinical trial utilizing CYWC628 for treatment of diabetic foot ulcers in Australia in the second half of 2025.
• Complete the clinical trial in the first quarter of 2026.
• Carry out experiments to demonstrate the potential of using the CYWC628 master cell bank for use with the manufacturing of the CybroCell drug product.
• Amend the IND clearance with the FDA for the planned Phase I clinical trial.

Key Dates

Keywords

FibroBiologics, fibroblast, cell therapy, clinical trials, research and development, financial results, CYWC628, CYMS101, CybroCell, SEPA, convertible notes, going concern